| Drug General Information |
| Drug ID |
D0OP1K
|
| Former ID |
DNC000754
|
| Drug Name |
Hydroxyfasudil
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H17N3O3S
|
| Canonical SMILES |
C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O
|
| InChI |
1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)
|
| InChIKey |
ZAVGJDAFCZAWSZ-UHFFFAOYSA-N
|
| CAS Number |
CAS 105628-72-6
|
| PubChem Compound ID |
|
| PubChem Substance ID |
8028483, 8142703, 10062426, 14898703, 26755032, 29216379, 36398431, 46394055, 46394057, 46508609, 46514396, 48318734, 49961266, 57354139, 80688326, 104249468, 111650847, 118050706, 121278723, 125658888, 126660180, 129876018, 134224807, 134339663, 134340095, 135138692, 137008564, 137183652, 139403950, 143382892, 152040678, 160967691, 163366710, 172657822, 177748411, 179236068, 184596704, 201503199, 210275006, 210280644, 223573585, 226494738, 242281871, 252475194
|
| Target and Pathway |
| Target(s) |
Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
TGF-beta signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
|
RhoA signaling pathway
|
|
Noncanonical Wnt signaling pathway
|
|
EPHB forward signaling
|
|
Thromboxane A2 receptor signaling
|
|
PAR4-mediated thrombin signaling events
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
EPHA forward signaling
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
N-cadherin signaling events
|
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKs
|
|
WikiPathways
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
AGE/RAGE pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
Apoptotic execution phase
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004 Jan 9;94(1):46-52. Epub 2003 Nov 13. |
|---|
